<DOC>
	<DOCNO>NCT01383005</DOCNO>
	<brief_summary>Both twice-a-day ( BID ) once-a-day ( QD ) dose approve Europe protease inhibitor lopinavir/ritonavir ( LPV/r ; Kaletra® ) . Since once-a-day dose actually driver human immunodeficiency virus ( HIV ) -infected patient request specific antiretroviral , aim study assess patient 's perception adherence Kaletra once-a-day , well factor relate .</brief_summary>
	<brief_title>Treatment Perception QD ( Once Day ) Dosed Kaletra ( Tablets )</brief_title>
	<detailed_description>This multicenter , post-marketing , observational , cross-sectional ( single visit ) study HIV-infected patient treat combination antiretroviral treatment ( ART ) contain LPV/r 200/50 mg tablet dose QD least 12 week assess participant ' satisfaction adherence level LPV/r QD ART measure specific validate participant questionnaire . As non-interventional study , decision enroll participant separate decision treat subject LPV/r . Prescription LPV/r duration treatment responsibility treat physician . In addition , overall study population compare Cohort 2 ( 394 patient LPV/r BID ≥3 month &lt; 2 year ) KAPITAL2 , post-marketing observational , cross-sectional , single visit , multicenter , national study . For detail study , please see : Casado JL , Griffa L , Cabrero E , Burgos A , Norton M KAPITAL 2 Collaborative Group . A study treatment satisfaction report patient lopinavir/r anchor regimen physician provide HIV care ( KAPITAL 2 ) . 9th International Congress Drug Therapy HIV Infection . 9th International Congress Drug Therapy HIV Infection . Glasgow , 2008. # P080 .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Inclusion criterion : 1 . Men woman age 18 year old , HIVinfected . 2 . Patients LPV/r Highly Active AntiRetroviral Therapy ( HAART ) 3 24 month study visit : Cohort 1 : patient LPV/r QD since start LPV/r regimen naïve protease inhibitor ( PI ) therapy . * Cohort 2 : patient previously start LPV/r BID ( maximum 24 month study ) switch LPV/r QD ( least 3 month study visit ) . * 3 . Patients able complete questionnaire . 4 . Patients signed/dated informed consent participate study . NOTE : Patients take LPV/r QD 3 protease inhibitor mutation time treatment LPV/r dosing initiate . Exclusion criterion : 1 . Patients LPV/r monotherapy bitherapy BID dosing time study visit . 2 . Patients use another LPV/r formulation different 200/50 LPV/r mg tablet . 3 . Patients participate clinical trial postmarketing observational study ( PMOS ) . 4 . Patients unable read and/or write . 5 . Patients treatment interruption . Patients stop LPVtherapy 3 month 12 month precede study visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Treatment satisfaction</keyword>
	<keyword>Adherence treatment</keyword>
</DOC>